Radiometer to Sponsor World Sepsis Day 2016
News Sep 08, 2016
Radiometer is proud to announce that it is sponsoring this year’s World Sepsis Day on the 13th September, continuing its commitment to the fight against this life-threatening medical condition. This initiative is a key part of the drive to improve outcomes for sepsis – the number one cause of preventable deaths worldwide – highlighting the significant diagnostic challenges and importance of early intervention.
Sepsis affects over 25 million people every year, proving fatal in almost a third of cases. The Global Sepsis Alliance aims to save 800,000 lives a year by promoting events such as World Sepsis Day. This sponsorship agreement is part of Radiometer’s ongoing pledge to improve global healthcare, by increasing awareness of sepsis and providing medical professionals with the tools to help identify and treat the condition sooner, improving the odds of recovery.
Radiometer offers the broadest point-of-care diagnostic menu to support the current guidelines for the diagnosis and treatment of sepsis. Last year, the company launched a rapid procalcitonin (PCT) assay – the biomarker of choice to aid the diagnosis of sepsis – which offers results in less than 21 minutes with the AQT90 FLEX analyzer. Together with Radiometer’s portfolio of other relevant diagnostic and prognostic markers – including white blood cell count, CRP, creatinine, bilirubin, lactate and blood gases – this is helping to significantly improve turnaround times for sepsis diagnosis, improving the odds of patients making a full recovery.
Henrik Schimmell, President of Radiometer, commented: “We are delighted to be sponsoring the World Sepsis Day, as it complements our ongoing commitment to help improve global healthcare by providing reliable, fast and easy patient diagnosis. By raising awareness of sepsis, we can help to ensure that more people survive this potentially fatal condition.”
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE